PVS 10200

Drug Profile

PVS 10200

Alternative Names: PVS-10200

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pervasis Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 19 Apr 2012 Shire acquires all the assets of Pervasis Therapeutics
  • 07 Apr 2010 Phase-I/II clinical trials in Peripheral arterial disorders in France (Parenteral)
  • 12 Oct 2009 Phase-I clinical trials in Peripheral arterial disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top